Actively Recruiting
A Phase 1 Randomized, Placebo-Controlled Study Evaluating Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ACI-19764 in Healthy Adults and Those With Cardiovascular Risk Factors
Led by AC Immune SA · Updated on 2026-09-02
114
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying ACI-19764, a brain-penetrant NLRP3 inhibitor, to evaluate its safety, tolerability, absorption, metabolism, and effects on immune system markers. This Phase 1 randomized, placebo-controlled trial includes healthy volunteers and participants with cardiovascular risk factors, aiming to understand how the drug behaves in the body and its impact on specific blood markers. The study is divided into three parts. Part A tests single ascending doses in healthy male participants, with observation onsite for 3 days and follow-up visits. Part B involves multiple ascending doses over 14 days in healthy males and females, with 17 days onsite and follow-up blood tests. Part C enrolls participants with cardiovascular risk factors who take daily doses orally for 28 days, including confined onsite stays and ambulatory visits. Placebo groups are included in all parts for comparison. Participants undergo screening, dosing, and observation periods with frequent blood tests, vital sign monitoring, ECGs, and assessments of suicidal ideation. Pharmacokinetics and pharmacodynamics of ACI-19764 are measured at multiple time points. Safety follow-up calls occur about three weeks after treatment. Total participation varies by study part but includes onsite confinement and ambulatory visits over several weeks.
CONDITIONS
Brief Title
A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors
Research Team
A
AC Immune Clinical Lead
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here